Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

943

Participants

Timeline

Start Date

March 31, 2020

Primary Completion Date

September 24, 2020

Study Completion Date

October 8, 2020

Conditions
COVID-19Corona Virus InfectionSARS (Severe Acute Respiratory Syndrome)SARS-CoV-2
Interventions
DRUG

Hydroxychloroquine Sulfate

Eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy

DRUG

Ascorbic Acid

Eligible participants in a household randomized to this study arm will receive ascorbic acid therapy.

Trial Locations (8)

10016

NYU Langone Health, New York

13210

SUNY Upstate Medical University, Syracuse

21201

University of Maryland, Baltimore, Baltimore

70118

Tulane, New Orleans

90095

University of California Los Angeles, Los Angeles

98104

University of Washington, Coordinating Center, Seattle

UW Virology Research Clinic, Seattle

02215

Boston University, Boston

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

University of Washington

OTHER

NCT04328961 - Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP) | Biotech Hunter | Biotech Hunter